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Background: As a result of the increasing prevalence of obesity in the UK, anesthetists are increasingly
encountering overweight and obese patients in routine practice. There is currently a paucity of evidence to guide
best clinical practice for anesthetists managing overweight and obese patients. The current guidelines from the
Association of Anaesthetists of Great Britain and Ireland (AAGBI), entitled Peri-Operative Management of the Morbidly
Obese Patient, give an excellent overview of organizational issues, but leave much clinical detail to the discretion of
the individual clinician.
Methods: In May 2010, a panel of experts convened to develop consensus on anesthesia of overweight, obese and
morbidly obese patients, in consultation with the Society for Obesity and Bariatric Anaesthesia (SOBA). All Panel
members are practicing clinicians from recognized bariatric surgical training centers and have extensive experience
of anesthesia for obese patients. This statement aims to provide guiding principles on best practice for this
challenging patient demographic, and to increase awareness of current issues so that these can be addressed more
appropriately.
Results: In this document, we emphasize key principles for best practice, rather than giving prescriptive guidance
and specific regimens for all clinical eventualities. We provide evidence-based justification for best-practice
techniques, where this exists. In areas for which there is no evidence, but there is clear consensus, we offer this as
guidance. We also aim to dispel misconceptions that have arisen in the anesthetic practice of overweight, obese,
and morbidly obese patients.
Conclusion: Ultimately, the choice of specific technique depends on clinician experience, patient characteristics,
and center facilities. As well as providing guiding principles for anesthesia, this consensus statement also highlights
other areas where anesthetists can contribute towards the enhanced recovery and overall quality of patient care.* Correspondence: m.margarson@nhs.net
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Owing to the increasing prevalence of obesity in the UK,
anesthetists are increasingly encountering overweight
and obese patients in routine practice. However, there is
currently little clinical guidance for anesthetists in the
management of this patient group. Therefore, in May
2010, a panel of experts convened to develop consensus
on anesthesia of overweight, obese, and morbidly obese
patients, in consultation with the Society for Obesity
and Bariatric Anaesthesia (SOBA). All panel members
are practicing clinicians from recognized bariatric surgi-
cal training centers, and have significant experience in
anesthesia of overweight and obese patients.
Changing patient demographic
Figure 1 shows the prevalence of obesity among adults
in England between 1993 and 2007 [1]. The Foresight
report, Tackling Obesities: Future Choices, estimated that
36% of men and 28% of women would be obese by 2015,
and these figures would rise to 47% and 36%, respect-
ively, by 2025 [2]. The Foresight report also estimated
that the annual direct and indirect costs of obesity could
reach £37 billion by 2025, consuming almost 12% of the
total National Health Service (NHS) budget [2]. Recent
US research shows that almost 17% of medical expend-
iture in the US goes towards the treatment of illnesses
caused by obesity, almost double previous estimates [3].
Therefore, it is imperative that anesthetists become fa-
miliar with managing overweight and obese patients and
understand the wider implications for the NHS.
Lack of guidance in the field
There is currently a paucity of evidence regarding best
clinical practice for anesthetists managing overweight
and obese patients. The current guidelines from the As-
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republished with permission of The Health and Social Care Information Cen(AAGBI), entitled Peri-Operative Management of the
Morbidly Obese Patient, give an excellent overview of
organizational issues, but leave much clinical detail to
the discretion of the individual clinician [4].
Aim and scope of this statement
This statement aims to provide guiding principles on
optimal care for this changing patient demographic, and
to increase awareness of current issues so that clinical
challenges can be addressed more appropriately. In this
document, we aim to emphasize key principles for best
practice, rather than giving prescriptive guidance and
specific regimens for all clinical eventualities. We pro-
vide evidence-based justification for best-practice tech-
niques, where this exists. In areas for which there is no
evidence, but there is clear consensus, we offer this as
guidance. We also aim to dispel misconceptions that
have arisen in anesthetic practice of overweight, obese,
and morbidly obese patients. Ultimately, choice of the
specific technique depends on clinician experience,
patient characteristics, and center facilities.
The enhanced recovery programme
As well as providing guiding principles for anesthesia, we
hope that this consensus statement will highlight other
areas in which anesthetists can contribute towards
enhanced recovery and the overall quality of patient care.
The fundamental principles of best practice in
anesthesia for overweight and obese patients are at the
very heart of the Enhanced Recovery Programme:
 Better outcome and shortened length of stay for the
patient, including early mobilization
 Structured approach for optimal pre-operative, peri-
operative and post-operative care
 Reduction in the physiological stress of surgery.ear
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ational Health Service Information Centre [1]. Copyright ©2012,
tre. All rights reserved.
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these principles will deliver benefit both to individual pa-
tients and to the NHS as a whole. Because the healthcare
needs of overweight and obese patients place a growing
burden on the NHS, there is a clear need to bring clinical
practice into alignment with the Enhanced Recovery
Programme to focus on quality, improve productivity,
eliminate waste, and curtail spiraling costs.Definition of obesity
The principles set out in this consensus statement apply
according to: 1) the severity of obesity and 2) the physio-
logical effects in terms of comorbidities. We will not
address specific categories of obesity. However, it is useful
to define classifications of overweight and obesity.
Body mass index (BMI) is the most common method
of classifying adult weight. It is defined as weight in kilo-
grams divided by the height in meters squared (kg/m2).
Table 1 shows BMI ranges as defined by the WHO [5].
The medical literature gives further categories, including
superobese (50 to 59.9 kg/m2), super-superobese (60 to
69.9 kg/m2) and hyperobese (>70 kg/m2) [6].
BMI is not an ideal measurement of obesity. It fails to
take into account variations in body proportions in dif-
ferent populations. The WHO has investigated the need
for developing different BMI cut-off points for defini-
tions of obesity in different ethnic groups, including
Asian and Pacific populations. A WHO Expert Consult-
ation recommended additional cut-off points, which
should be used in conjunction with the principal cut-off
points in some populations [7].
Simple linear measurements, such as girth or neck
circumference, are often more clinically relevant than
BMI in measurement of obesity levels, because they may
give a better idea of fat distribution. Consideration of fat
distribution is very important, and although there is a
whole spectrum of types of distribution, two major types
are used for classification: android and gynecoid fat dis-
tribution, also knows as ‘apples’ and ‘pears’. Although
the terms ‘android’ and ‘gynecoid’ refer to the typicalTable 1 WHO international classification of adult







Obese class I 30–35
Obese class II 35–40
Obese class III (morbidly obese) ≥40male (centripetal) and female (peripheral) fat distribu-
tions, both distributions are seen in both genders.
The android type is of greater pathophysiological
significance. It describes a physique in which the weight
is carried on the trunk and there is a high intraperitoneal
fat content. The patient is likely to have an increased
neck circumference, but with little fat distributed on the
arms and legs. A patient with an android fat distribution
may have a modest BMI, of around 50 kg/m2, yet may
have minimal physiological reserve and be at extreme
risk of peri-operative death.
In a person with gynecoid fat distribution, more weight
is carried on the arms, legs, and buttocks, and abdominal
fat is predominantly extraperitoneal. Patients with very
high BMIs will usually have this type of fat distribution
and, paradoxically, may be at lower risk of mortality than
those with an android fat distribution.
Results and discussion
Introduction to best-practice anesthetic techniques
A key principle for anesthesia is the employment of tech-
niques that are familiar, reproducible, and safe. The
anesthetist should not necessarily have to change practice
just because the patient is larger than the average they
encounter. Rather, a better outcome may be achieved by
awareness of the issues that may arise in this population.
The risk should not be exacerbated by incorporating new
or unfamiliar techniques.
A second key principle is maintaining control and min-
imizing periods of potential risk or instability. In particular,
care should be taken during the transition from spontan-
eous breathing to controlled ventilation during induction,
and during the periods of emergence and extubation.
Techniques should incorporate Enhanced Recovery
principles to provide optimal care.
Premedication and preparation techniques
Antacid prophylaxis with histamine 2 antagonists or
proton-pump inhibitors may be used as indicated, for
example in patients with pre-existing, untreated reflux.
This is often continued into the post-operative period.
Pre-emptive analgesia with paracetamol and a non-
steroidal anti-inflammatory (NSAID) can be considered.
Sedative premedication should be avoided.
It is best practice to induce anesthesia in theatre and
not in an anesthetic room, thereby minimizing move-
ment of the unconscious obese patient. Patients should
be positioned in a 20 to 30 degree head-up position at
induction, with sufficient support behind the shoulders
and head to optimize intubation conditions [8]. Position-
ing the arms out laterally on arm supports is often help-
ful, both in terms of optimizing anesthetic access and
allowing the surgeon easier access to the abdomen. At-
tention to pressure points is essential in the morbidly
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facilitate post-operative transfer is very useful. If a steep
head-up posture is required, a footplate should be posi-
tioned to prevent sliding, and the patient should be
securely strapped to the operating table.
Thromboprophylaxis should be instigated using com-
pression techniques to cover the peri-operative period. The
standard is intermittent pneumatic calf compression. Pre-
operative low molecular weight heparins may be indicated
in high-risk patients, and is recommended postoperatively
in all cases. The ideal time for initial dose administration is
probably 4 hours post-surgery, but this may be delayed
in patients with marked surgical bleeding [9]. There is
increasing evidence that thromboprophylaxis with low mo-
lecular weight heparins should be routinely continued for
around 10 days postoperatively in all patients undergoing
gastric bypass or other major procedures. In selected cases
where patients are at very high risk or are unable to toler-
ate heparins, there may be a role for temporary inferior
vena cava filter placement [10].
Induction agents, neuromuscular blocking agents, and
ventilation
The choice of induction agent depends on familiarity.
The agents and technique used should be amenable to a
stable induction that minimizes risk of desaturation.
There has been considerable debate regarding the tim-
ing of administration of neuromuscular blocking agents in
cases where facemask ventilation is initially awkward.
Traditional teaching advocated that when difficult intub-
ation or ventilation is anticipated, administration of such
neuromuscular blocking agents should be delayed until
after adequate facemask ventilation has been achieved
[11]. However, there is increasing consensus that facemask
ventilation becomes easier once neuromuscular blocking
agents have been given [12]. Difficult facemask ventilation
is more common and much more serious in overweight
and obese patients. Therefore, for patients in whom awake
intubation is not felt to be indicated, neuromuscular
blocking agents should be given early in the induction
sequence.
The time between administration of the neuromuscu-
lar blocking agent and initiation of ventilation should be
minimized in order to maintain adequate control.
Facemask ventilation should be performed carefully to
avoid distension of the stomach and bowel, and there
should be a low threshold for the use of airway adjuncts,
particularly a Guedel airway, to aid ventilation. A 20 to
30 degree head-up posture during induction facilitates
ventilation in all patients, as well as assisting in intub-
ation. When difficulties in facemask ventilation are
anticipated, there may be an advantage in the use of
higher-dose rocuronium or even suxamethonium to
enable very early intubation.Monitoring of neuromuscular blockade during surgery
is advised. It is important to use a neuromuscular
blocking agent with a predictable duration of action in
order to avoid residual neuromuscular blockade during
the recovery period. Common approaches include the
use of agents such as atracurium, or an aminosteroid
such as vecuronium or rocuronium. The longer duration
of action and delay in offset of the aminosteroids is now
counterbalanced by the availability of the γ-cyclodextrin
reversal agent, sugammadex. Although currently not
routine, the use of cyclodextrins to reverse neuromuscu-
lar blockade may have benefits and, in the future, may
become more prevalent.
Maintenance of adequate relaxation for surgery is en-
hanced with remifentanil, and the use of this agent has
the additional benefit of reducing volatile or propofol
requirements.
Rapid sequence induction
Rapid sequence induction (RSI) has historically been a
common procedure in obese patients, and remains the
technique of choice in patients with a history suggestive
of active reflux. However, in patients without such a
history, RSI is not required. A comprehensive review by
Freid [13] concluded that RSI offered no benefit in
fasted elective surgery patients who have no risk factors
for reflux other than obesity or sleep apnea syndrome.
Airway control
Patients who are morbidly obese have a reduced functional
residual capacity and an increased basal oxygen utilization
[14,15]. Therefore, once they become apneic, they experi-
ence rapid and early desaturation. Pre-oxygenation is
mandatory as a standard of care, including in the head-up
or ramped position, and is ideally performed using a tight-
fitting facemask. Where this is not tolerated by the patient,
an alternative technique should be used to achieve the best
pre-oxygenation possible.
The most important consideration during induction of
anesthesia and intubation is to maintain control of the air-
way. A technique should be used that minimizes the tran-
sition time from the airway being maintained by an awake
patient to the airway being secured by the anesthetist. We
advocate early use of a neuromuscular blocking agent,
although in selected individuals there may be a role for
awake fibre-optic intubation (FOI). Loss of airway control
is most likely to occur in patients who are inadequately
anesthetized and inadequately paralyzed.
There is a misconception that intubation in morbidly
obese patients is much more difficult than intubation
in non-obese patients. There is little evidence for
this. Often, facemask ventilation and maintenance of
adequate oxygenation is far more likely to be an issue.
Several studies have shown that BMI alone is not a risk
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severely overweight were not more difficult to intubate
than other patients [8,16,17]. The strongest predictors of
difficult intubation are: 1) male gender; 2) large neck cir-
cumference [8,18]; 3) limited neck mobility; 4) crowded
mouth, as indicated by a high Mallampati score [8,18];
and 5) obstructive sleep apnea.
Reliable airway control is best achieved by: 1) Use of
an appropriate relaxant and dose; 2) good positioning,
including head elevation. ramping, and head-up tilt; and
3) help of a skilled assistant familiar with bariatric and
airway issues.
FOI is seldom indicated, except for expected difficult in-
tubation (similar considerations as for non-obese patients)
or expected significant difficulty with facemask ventilation.
The role of airway adjuncts, such as the video laryngo-
scope, is under evaluation. Such airway adjuncts may
prove extremely valuable, but at present, their use de-
pends on the skills of the individual clinician. Principles
of management of the ‘can’t intubate, can’t ventilate’
(CICV) scenario have been outlined by the Difficult Air-
way Society. These should be followed when a patient
under general anesthesia with muscle relaxation cannot
be intubated by direct laryngoscopy and mask ventila-
tion is difficult/impossible [19].
Maintenance
Options for maintenance techniques include either
short-acting volatiles or total intravenous anesthesia
(TIVA). The choice of technique is underpinned by a
number of key principles.
Controllability
Because modern volatile agents have low blood-gas and
oil-gas solubilities, their pharmacokinetics are only moder-
ately influenced by obesity. However, the rapidity of onset
and offset of anesthesia conferred by very low blood-gas
solubility (for example, with sevoflurane or desflurane) is
more marked in obese patients. Consequently, depth of
anesthesia can be more rapidly titrated using these agents.
In addition, volatile agents are titrated against an individ-
ual’s measured end-tidal concentration, whereas TIVA is
titrated against an effect-site concentration derived from a
population-based kinetic model. There is no widespread
agreement on the kinetic model beyond 120 kg, and thus
requires the anesthetist to use a degree of estimation when
utilising propofol infusion techniques. Whenever TIVA is
used, depth of anesthesia monitoring is recommended to
facilitate titration of anesthesia.
Rapid wake-up: patient regains control of airway quickly
Recovery from anesthesia is often prolonged in obese
patients [20]. These patients are also at increased risk of
both aspiration and acute upper-airway obstruction aftertracheal extubation [21]. These are rarely occurring com-
plication, but are potentially catastrophic. Therefore, very
rapid post-operative recovery is desirable in these patients
to ensure early efficient coughing and to decrease the risk
of post-operative respiratory complications.
A recent meta-analysis comparing short-acting volatile
agents showed that desflurane reduced mean time to
extubation by approximately 25% relative to sevoflurane.
There was a further reduction in the variability of
extubation time, with the group receiving desflurane
having significantly fewer patients with a prolonged
(15 minutes or longer) interval between the end of
surgery and extubation [22].
Safe return of airway and swallowing reflexes has also
been shown to occur more rapidly with short-acting
volatiles. The time from anesthetic discontinuation to
recovery of the ability to swallow was significantly
shorter after desflurane anesthesia, and this effect was
most marked in those patients with greater BMI and
prolonged procedures [23].
Minimal respiratory depression
Anesthetics that allow for rapid emergence from
anesthesia and rapid recovery of airway control tend to
produce the least post-operative respiratory depression,
therefore aiding carbon dioxide (CO2) clearance, restor-
ation of deep breathing, and effective cough.
Inhalation anesthetics have a dose-dependent effect on
respiratory drive and reflexes. In particular, they accen-
tuate the depressant effects of opioids on the responses
to hypoxia and hypercapnia. Previous work has shown
that residual volatiles at the 0.1 minimum alveolar con-
centration may significantly depress the hypoxic drive in
normal subjects, and these effects are likely to be exag-
gerated in patient who are morbidly obese. The ultra-
short-acting volatiles that are the least metabolized have
the smallest effect in depressing this hypoxic response
[24]. Similarly, minimally metabolized agents do not
share the issues of accumulation of volatile metabolites
(such as compound A), and thus can be used at very low
flow rates to maximize efficiency.
Minimal compromise of hemodynamic stability
All maintenance agents, both volatile and intravenous,
cause vasodilatation and a reduction in blood pressure.
With some maintenance regimens, this can be marked.
In patients with reduced cardiac reserve, the use of
agents with a degree of sympathetic activity may give a
more stable peri-operative course, and could reduce the
excessive use of fluids and vasopressor agents [25].
Early mobilization of patients after the procedure
The very rapid offset time and rapid awakening after
maintenance with the ultra-short-acting volatile agents
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possible, morbidly obese patients should be sat out in a
chair by their bed later in the day of surgery. This is im-
portant for reducing post-operative complications, espe-
cially deep-vein thrombosis, but erect posture also appears
to speed up the recovery of gut function and certainly has
beneficial effects on post-operative respiratory mechanics.
A key assumption of the Enhanced Recovery Programme,
and widely accepted, is that early ambulation translates
into earlier discharge [26].
Extubation
The extubation technique used should aim to ensure
that the transition from a controlled, intubated airway to
a patient-protected airway and spontaneous ventilation
is as quick, safe, and smooth as possible. Airway control
around the time of extubation poses greater risks to
overweight and obese patients than to lean patients.
The timing of extubation in these patients should be
based on the balance of risk of loss of the airway versus
patient comfort. Patients with significant respiratory co-
morbidity will have to be almost fully awake and coughing
on the tube before extubation can be allowed; however,
this induce marked hypertension and cardiovascular
stress. In order to allow slightly earlier extubation while
minimizing the risks of failure, the following points should
be observed.
 Use as little opioid as possible, or use short-acting
opioids that clear rapidly, such as remifentanil.
 Minimize residual anesthetic at extubation.
 Ensure adequate reversal of neuromuscular blocking
agents with the use of appropriate reversal agents
(and confirm with a nerve stimulator if in doubt).
 Position the patient in an almost upright position to
maximize respiratory mechanics; this may require
lateral support with pillows to ensure the patient
does not fall to one side.
 Consider using respiratory stimulants immediately
after extubation to prevent hypoventilation and CO2
retention in patients likely to have an obtunded
respiratory drive.
Analgesia
One of the central tenets of the Enhanced Recovery
Programme is that there should be a multimodal ap-
proach to immediate post-operative and peri-operative
pain relief in order to reduce side effects of individual
agents. Central to analgesia management of overweight
and obese patients are the following points:
 Minimize the use of long-acting opioids.
 Use minimally invasive surgery with local
anesthetic infiltration. Use appropriate dosing of non-opioid analgesics.
 The paracetamol dose given to overweight and
obese patients should be similar to that of non-
obese patients. However, clearance of paracetamol in
overweight and obese patients is increased [27],
therefore dosing may need to be more frequent.
 Use co-analgesic agents.
The post-operative pain reported by obese patients, and
thus their analgesic requirement, is often less than
expected [28]. This has been attributed to high motivation.
Epidural analgesia is technically difficult, and may delay
mobilization. This carries disadvantages for overweight
and obese patients undergoing bariatric surgery, unless a
large open wound is anticipated. Patient-controlled anal-
gesia and epidural analgesia are rarely necessary, in part
owing to increasing use of minimally invasive surgery and
the availability of other analgesia options.
Paracetamol is a frequently used adjunct and has been
shown to be markedly morphine-sparing in bariatric sur-
gery. The risk of toxic metabolites from high-dose para-
cetamol is low, but in patients with known liver disease
or who are in a malnourished state (rare in the morbidly
obese population), the dose should adhere to the British
National Formulary maximum of 4 g/day. Many centers
use larger doses in very large patients, and doses of 6 g
on the day of surgery are routine in some centers.
NSAIDs are effective as part of a multimodal regimen,
but they should be used with caution in patients at high
risk of post-operative renal dysfunction. If used judi-
ciously, the potential bleeding risk of NSAIDs should be
minimal. Traditionally, many clinicians have avoided
NSAIDs in patients with a history of asthma. Aside from
cases of known sensitivity, there is very little evidence to
support this practice [29,30]. The use of diclofenac or
ketorolac seems appropriate.
Gabapentin and pregabalin are frequently used as
co-analgesics, but appear to be markedly sedating and, in
the obese patient who needs to awaken rapidly and protect
their airway, this side effect may be unacceptable [31].
Dexmedetomidine has just become available in the
UK, and it appears to be a useful co-analgesic agent,
especially in obtunding sympathetic responses. The roles
of ketamine and lidocaine infusions are under investiga-
tion. These might prove useful in the future.
Anti-emetics
Post-operative nausea and vomiting (PONV) is a common
complication of general anesthesia, which is extremely un-
pleasant for the patient and can lead to increased
recovery-room time and extended hospital stay. Manipula-
tion of the upper stomach, such as occurs in bariatric sur-
gery, is associated with a significant incidence of nausea,
thus good anti-emetic therapy is highly desirable [32].
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5-hydroxytryptamine 3 (5-HT3) receptor antagonists as
first-line preventive agents in patients categorized as high
risk [33]. Ondansetron is the most frequently used, but its
relatively short duration of action means that this drug
should be given towards the end of the procedure. In
procedures and patients with a high risk of PONV, use of
multiple anti-emetics is recommended, and the combin-
ation of a 5-HT3 antagonist (for example, ondansetron)
and dexamethasone is a frequently chosen pairing [34].
There is further benefit to be gained with the use of triple
anti-emetic therapy; additional agents commonly added
include cyclizine and metoclopramide.
Nitrous oxide (although rarely used in UK bariatric sur-
gery) has been implicated as a risk factor for PONV, and
should probably be avoided. Likewise, opioid use should
be kept to a minimum. In patients with a strong history of
PONV, use of a continuous infusion of propofol may be
indicated.
The contribution of nausea to the delay in patient
mobilization and patient discomfort is very important, and
the best anti-emetic regimen is still to be determined. The
role of other anti-emetic therapies, including hyoscine
patches or pressure-point techniques, may be considered.
It is important to remember that nausea may be a symp-
tom of hypotension and of hypoglycemia in patients with
diabetes.
Priorities for further clinical research
There is a pressing need for further clinical research in
the management of this challenging patient group.
Although much has been published on the underlying
molecular mechanisms of obesity, the way in which
these processes relate to pathophysiology of the disease
and, in particular, how they affect anesthesia and the peri-
operative course is poorly understood. We recommend a
program of structured research covering: 1) mechanistic
investigation: molecular and pathophysiologic mecha-
nisms to affect peri-operative medicine; 2) potential dis-
ease response modifiers; and 3) a program of translational
research to bring the bench to the bedside.
We suggest the following areas as priorities for clinical
research.
 Identification of how co-morbidities significantly
affect the peri-operative course, for example, heart
failure and ischemic heart disease; and particularly
sleep apnoea / anaesthetic agent interactions and the
increased risk of post-operative respiratory
depression.
 Design of anesthetic strategies to minimize risk of
peri-operative morbidity, particularly nausea.
 Improvement of tests that predict difficult
intubation. Definition of the role of co-analgesic agents in
reducing opioid requirements and discomfort.
Conclusions
In this consensus statement, we have addressed the
clinical issues that anesthetists are increasingly likely to
encounter, given the rising prevalence of obesity in the
UK. We have emphasized the following key principles
for best practice.
 Better outcomes may be achieved by awareness of
the key issues that may arise in this patient
population.
 The anesthetist should maintain control of the
patient and minimize periods of potential risk or
instability.
 Techniques that are familiar, reproducible, and safe
should be used in preference to unfamiliar
techniques that may enhance the risk to the patient.
 Anesthetic techniques should be used that
encourage better outcomes, early mobilization, and
shortened length of hospital stay.
These guiding principles align with enhanced surgical
recovery.
Given the correct care, anesthesia of overweight and
obese patients is straightforward. However, problems
have greater potential to escalate with this patient
population than with other patient populations. With an
understanding of the issues addressed in this consensus
statement, and with appropriate use of techniques and
agents, these patients can be managed as safely as
patients of normal weight.
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